Julie M Vose MD MBA

Hematologic Oncology

Payne Distinguished Chair of Oncology Professor of Medicine

986840 Nebraska Medical CenterBuffett Cancer CenterOmaha, NE 68198
Phone+1 402-559-5600
Fax+1 402-559-4835

Dr. Vose is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vose's full profile Already have an account?

Summary

Dr. Julie Vose is a Hematologist/Oncologist based in Omaha, NE, specializing in hematologic malignancies, cellular therapy, and novel treatments for lymphoma. She completed her residency in internal medicine and fellowship in hematology and medical oncology at the University of Nebraska Medical Center College of Medicine. She holds an MBA in Health Administration from the University of Colorado. Her areas of expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and cellular therapy among others. She has published hundreds of papers in reputable journals such as Blood, JCO, Blood Advances and Nature Communications. Dr. Vose has been involved in many clinical trials for novel agents and cellular therapies for treatment of lymphoma. She is also active in ASCO and other professional organizations.

Education & Training

University of Colorado Business SchoolM.B.A., Health Administration, 2009 - 2011
University of ColoradoMBA, Health Administration, 2009 - 2011
University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 1988 - 1990
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1984 - 1988
University of Nebraska College of MedicineClass of 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IA State Medical License 2021 - 2027
MO State Medical License 2024 - 2027
KS State Medical License 2024 - 2026
MT State Medical License 2024 - 2026
NE State Medical License 1984 - 2026
OK State Medical License 2024 - 2026
WY State Medical License 2024 - 2026
CA State Medical License 1998 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Start of enrollment: 1999 Sep 01
COMPLETED
PHASE3
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma Start of enrollment: 2000 May 01
COMPLETED
PHASE2
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 1999 Jun 25
COMPLETED
PHASE2

Publications & Presentations

PubMed

Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.
Paula M Fracasso, Nicole L Simone, Stephanie J Si Lim, Karen L Reckamp, Julie Ann Sosa
JCO Oncology Practice. 2026-07-01
1 citations
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Krish Patel, Julie M Vose, Sunita D Nasta, Jennifer R Brown, Kami J Maddocks
Blood Advances. 2026-04-14
3 citations
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Nirav N Shah, Pier Luigi Zinzani, Michael Wang, Sunita D Nasta, Ewa Lech-Maranda
Blood Advances. 2025-12-09

Journal Articles

Angioimmunoblastic T-cell lymphoma management
Mosalpuria K, Bociek RG, Vose JM, Semin Hematol, 1/1/2014
A multicenter study of primary breast diffuse large B-cell lymphoma in the rituximab era
Hosein PJ, Maragulia JC, Salzburg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirahni R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz Ad, Lossos IS, Br J Haematol, 1/1/2014
Phase I/II study of Velcade BEAM (V-BEAM) and autologous hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin lymphoma (NHL), transformed o...
William BM, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO, Vose JM, Biol Blood Marrow Trans, 1/1/2014

Books/Book Chapters

Targeted Therapy in Translational Cancer Research
Chapter: Lymphoma and targeted therapies
Page 169 - 176Smith SM, Vose JMJohn Wiley & Sons, Inc., Hoboken, NJ2016
Bone Marrow Transplantation
Chapter: Hematopoietic stem cell transplantation for non-Hodgkin lymphoma
Page 1073 - 1095Bhatt VR, Vose JMElsevier2014
Neoplastic Diseases of the Blood
Chapter: Diagnosis and treatment of non-Hodgkin’s lymphoma of adults
Page 1027 - 1047Faber EA, Vose JM, Armitage JO, Bierman PJSpringer Science+Business Media, New York, NYEdition 5th,2013

Abstracts/Posters

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

American Board of Internal Medicine/ASCO Medical Oncology Learning and Assessment: The New...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Immunotherapy Combination Active in Patients with Large B-cell Lymphoma Who Are Not Eligible for Autologous Stem Cell TransplantNovember 10th, 2025
Medical Research Highlights, June 2025June 18th, 2025
$Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an Encore$
Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an EncoreMarch 28th, 2025

Grant Support

Flt-Pet/Ct For Therapy Monitoring Of DlbclNational Cancer Institute2011–2012
Nebraska/Kansas Blood And Marrow Transplant Research NetworkNational Heart, Lung, And Blood Institute2011
Nebraska Blood And Marrow Transplant Research NetworkNational Heart, Lung, And Blood Institute2001–2010
Core--Tissue ProcurementNational Cancer Institute1996–1999
Transplantation For Nhl--Comparison Of Psct And ABMTNational Cancer Institute1993–1996